ABSTRACT
Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges. Although the current understanding of its pathogenesis is still incomplete, research over the past 20 years has shown that genetic susceptibility may play an important role in the occurrence and development of DILI. In recent years, pharmacogenomics studies have further revealed the association between human leukocyte antigen (HLA) genes, some non-HLA genes, and hepatotoxicity from certain drugs. However, due to the lack of well-designed, prospective, large-sample cohort validation and low positive predictive values, there may still be some way to go before the current results can be truly translated into clinical practice for precise prediction and prevention of DILI risk.
Subject(s)
Humans , Genetic Predisposition to Disease , Prospective Studies , Risk Factors , Chemical and Drug Induced Liver Injury/genetics , Drug-Related Side Effects and Adverse Reactions , LiverABSTRACT
microRNAs (miRNAs) are endogenous, small noncoding RNA molecules discovered in animals, plants and viruses. They play a critical role in developmental and physiological processes and are implicated in the pathogenesis of many human cancers. Presently, human cancer, including colorectal cancer, is recognized as both a genetic and epigenetic disease. Changes induced by miRNAs are considered as epigenetic changes. Experiments were largely performed to analyze the colorectal microRNAome and bio-networking involving miRNAs. This review focuses on recent advances in colorectal miRNA expression profiles. Further, we discuss the regulatory network of miRNAs in the initiation and carcinogenesis of colon cancer in order to open up an avenue of anticancer therapy based on the epigenetic regulation by miRNAs.